Axa S.A. Lowers Stock Position in Thermo Fisher Scientific Inc. $TMO

Axa S.A. trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 437,727 shares of the medical research company’s stock after selling 82,824 shares during the period. Axa S.A.’s holdings in Thermo Fisher Scientific were worth $177,481,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. CBIZ Investment Advisory Services LLC grew its holdings in Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after acquiring an additional 33 shares in the last quarter. Anderson Financial Strategies LLC purchased a new stake in Thermo Fisher Scientific during the first quarter worth $30,000. Keystone Global Partners LLC acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter worth about $31,000. DiNuzzo Private Wealth Inc. lifted its stake in Thermo Fisher Scientific by 406.7% in the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after purchasing an additional 61 shares in the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd raised its position in shares of Thermo Fisher Scientific by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 77 shares of the medical research company’s stock valued at $38,000 after buying an additional 63 shares during the period. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.9%

Shares of NYSE TMO opened at $567.87 on Tuesday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The company has a market cap of $213.35 billion, a price-to-earnings ratio of 32.81, a P/E/G ratio of 4.19 and a beta of 0.90. The business has a fifty day simple moving average of $561.82 and a 200-day simple moving average of $487.30.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the previous year, the business posted $5.28 EPS. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its board has initiated a share buyback plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Frederick M. Lowery sold 6,912 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the transaction, the executive vice president directly owned 14,367 shares in the company, valued at approximately $8,360,731.98. This represents a 32.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michel Lagarde sold 22,046 shares of Thermo Fisher Scientific stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $563.56, for a total transaction of $12,424,243.76. Following the sale, the chief operating officer directly owned 84,117 shares of the company’s stock, valued at $47,404,976.52. This represents a 20.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 149,271 shares of company stock worth $86,507,282. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on TMO shares. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. TD Cowen upped their price target on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Wells Fargo & Company raised their price target on Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Morgan Stanley increased their target price on Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Finally, Citigroup raised their price target on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the company a “neutral” rating in a report on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $609.38.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.